Genetic Analysis of the APAF1 Gene in Male Germ Cell Tumors by Bala, Shashi et al.
Genetic Analysis of the APAF1 Gene in Male Germ
Cell Tumors
Shashi Bala1, Holt Oliver2, Beatrice Renault3, Kate Montgomery3, Shipra Dutta1, Pulivarthi Rao4,
Jane Houldsworth4, Raju Kucherlapati3, Xiaodong Wang2, R.S.K. Chaganti4, and V.V.V.S. Murty1*
1Department of Pathology, College of Physicians & Surgeons of Columbia University, New York, New York
2Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
3Department of Molecular Genetics, Albert Einstein College of Medicine, Bronx, New York
4Laboratory of Cancer Genetics and the Department of Human Genetics, Memorial Sloan-Kettering Cancer Center,
New York, New York
Cytogenetic and molecular analyses have shown that the chromosome band 12q22 is recurrently deleted in male germ cell
tumors (GCTs), indicating the presence of a candidate tumor suppressor gene (TSG) in this region. To identify the TSG, we
mapped the APAF1 gene, a proapoptotic mammalian homologue of ced-4, to chromosomal band 12q22, that suggested that this
might be the candidate deleted gene in GCTs. We further localized the gene between the polymorphic markers D12S1671
and D12S1082 at 12q22 to determine the role of APAF1 in the pathogenesis of GCT, and we characterized its normal genomic
structure and analyzed its alterations in GCTs. The APAF1 gene comprises 27 exons, with the coding region spanning 26. The
region containing APAF1 was found to be deleted in GCT by fluorescence in situ hybridization analysis, but without evidence
of coding sequence alterations. RT-PCR and Western blot analysis showed APAF1 gene expression at detectable levels in all
GCT cell lines analyzed. An aberrant-sized APAF1 protein was seen in one cell line. This and 2 other cell lines carrying APAF1
deletions also exhibited defects in dATP-mediated caspase-3 activation. Caspase-3 activity was effectively restored by addition
of recombinant caspase-9 and APAF1 proteins, and to a lesser extent by caspase-9 alone, but not by APAF1 alone. These data
do not support a TSG role for APAF1, but defects in other components of the apoptotic pathway that may be related to 12q22
deletion cannot be ruled out. Genes Chromosomes Cancer 28:258–268, 2000. © 2000 Wiley-Liss, Inc.
INTRODUCTION
Cytogenetic and molecular genetic studies on
male germ cell tumors (GCTs) have identified al-
terations affecting both the short and the long arms
of human chromosome 12 (Chaganti et al., 1996).
Cytogenetic studies have identified deletions af-
fecting 12q or monosomy of 12q in a high propor-
tion of GCTs (Murty et al., 1990; Samaniego et al.,
1990; Rodriguez et al., 1992). At the molecular
genetic level, restriction fragment length polymor-
phism (RFLP) studies identified loss of heterozy-
gosity (LOH) at two sites, 12q13 and 12q22, sug-
gesting the presence of at least two candidate
tumor suppressor genes (TSGs) on this chromo-
somal arm. In addition, homozygous deletion at
12q22 noted in a tumor further supported the view
that this region may harbor a candidate TSG
(Murty et al., 1992). More recently, fine mapping of
12q22 deletions identified an 830-kb minimal de-
letion between the markers D12S377 and
P382A8/AG (Murty et al., 1996, 1999). Similarly,
the 12q21-23 region has also been shown to exhibit
frequent LOH in pancreatic (Seymour et al., 1994;
Hahn et al., 1995; Kimura et al., 1996, 1998) and
gastrointestinal (Fey et al., 1989; Schneider et al.,
1995) carcinomas. These studies strongly indicated
the presence of one or more candidate TSGs at
12q22 that may be involved in the development of
GCT and other tumor types.
Genetic studies on the nematode C. elegans have
identified three genes, ced-3, ced-4, and ced-9, that
control the apoptotic cell death pathways, that are
conserved in vertebrates including man (Horvitz,
1999). CED-4 is required for development-associ-
ated cell death in the worm (Horvitz, 1999). CED-4
interacts physically with CED-3 to mediate proteo-
lytic activation of the immature procaspase CED-3
into enzymatically active forms (Hu et al., 1998;
Pan et al., 1998). In this cascade, CED-9 functions
upstream of CED-3 and CED-4 by preventing
their activation. Mutations that affect CED-4 oli-
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gomerization inactivate its ability to activate the
pro-CED-3 molecule and cause it to lose its pro-
apoptotic function (Yang et al., 1998). The CED-4
counterpart in man has been identified as APAF1
(Zou et al., 1997). CED-3 is similar to the mam-
malian caspase-3, whereas CED-9 is homologous to
the BCL2 family of genes. Human APAF1 mRNA
is a 7.2 kb transcript with a 3,582 nt coding region,
that encodes a 130 kDa protein (Zou et al., 1997).
The first 85 residues of the amino terminal of
APAF1 show identity with the amino terminal of
CED-3, whereas the following 320 amino acids
show similarity with CED-4. The COOH-terminal
region lacks homology to CED-4 and is composed
of 12 WD-40 repeats. APAF1, under the control of
BCL2, plays a crucial role in cell death pathways
through caspase activation. APAF1 has been shown
to participate in caspase-3 activation in a cyto-
chrome C-dependent manner (Li et al., 1997; Zou
et al., 1997, 1999). Thus, APAF1 functions down-
stream of CED-9 family members and upstream of
CED-3-like caspases in the apoptotic pathway.
Analysis of Apaf1-deficient mice exhibited re-
duced apoptosis in the embryonic brain, leading to
overgrowth, hyper-proliferation of neuronal cells,
cranio-facial abnormalities, and resistance to vari-
ous apoptotic stimuli and embryonic death by
E16.5 days. Evidently, the APAF1 gene plays a
central role in regulating programmed cell death
during mammalian development in mitochondria-
dependent apoptosis and is critical for regulation of
normal development. Therefore, germline muta-
tions in the gene can lead to abrogation of pro-
grammed cell death and developmental defects
(Cecconi et al., 1998; Yoshida et al., 1998). Simi-
larly, somatic mutations in APAF1 and other genes
involved in programmed cell death pathways can
confer a survival advantage, as exemplified by de-
letion of the caspase-3 gene in the MCF-7 breast
cancer cell line (Janicke et al., 1998). Recently, it
has been shown that inactivation of Apaf1 or
caspase-9 has been shown to lead to cellular trans-
formation and tumorigenesis (Soengas et al., 1999).
These data suggested that genetic alterations in
APAF1 or the other genes in the pathway disrupt
mechanisms of apoptosis and facilitate oncogenic
transformation.
In our physical mapping of the 12q22 region, we
assigned the APAF1 gene to the distal border of the
minimal deletion in GCT (Murty et al., 1999). In
view of its map position and function as a proapop-
totic factor, we considered APAF1 to be a good
candidate for the proposed TSG frequently de-
leted in GCTs. In this study, we report the exact
physical map position of APAF1 and its genomic
organization. In a genetic and functional analysis,
we also examined the role of APAF1 in the patho-
genesis of GCT and found no evidence in support
of a role for this gene.
MATERIALS AND METHODS
Physical Mapping and Identification of Intron-Exon
Boundaries
Our previous YAC and high-resolution physical
maps of the 12q22 deleted region in GCTs (Murty
et al., 1996, 1999; Kucherlapati et al., 1997) have
served as a framework in the present mapping
studies. During the generation of these maps, we
identified several BAC and PAC clones in this
region (Murty et al., 1999). We have sequenced
ends from a previously mapped PAC clone
P373G19 utilizing SP6 and T7 primers and de-
signed nonpolymorphic primer sets for each end
(sequences and primer information submitted to
GenBank, accession numbers AQ254952 and
AQ254953). Probes generated from these ends
were utilized for further screening of BAC and
PAC libraries (obtained from Dr. Pieter de Jong,
Roswell Park Cancer Institute). All of the clones
and markers isolated in this manner were placed
onto the map by STS-content analysis as described
(Murty et al., 1999).
For the identification of the intron-exon bound-
aries, genomic DNA prepared from a PAC (RPCI3-
379G19), and two BAC (RPCI11-396N22 and
RPCI11-7L14) clones containing the APAF1 gene
sequences, was utilized as template for sequencing.
A panel of 78 overlapping primers in both forward
and reverse orientation was designed spanning the
entire cDNA sequence. Intronic boundaries iden-
tified for exon 18 were based on the KIAA0413E
(EST AB007873) sequence. Sequences generated
in this manner were compared to cDNA by
BLAST searches to identify introns.
Southern Blot Analysis
Southern blot analysis was performed by stan-
dard methods after restriction digestion of DNA
isolated from P373G19, B396N22, and B7L14
clones. DNAs were subjected to EcoRI or HindIII
restriction digestion and transferred to nylon mem-
branes. These blots were hybridized with 32P-la-
beled APAF1 cDNA to assess the size of the
genomic region.
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Cell Lines and Tumor Tissues
Nine GCT cell lines (218A, 169A, 175A, 268A,
287A, 203B, 240A, 228A, and 154A) developed by
us (Rodriguez et al., 1992), and the 8 cell lines
(Tera-1, Tera-2, 833K-E, 2102E-P, 2102E-R,
2061H, 577M-F, and 577M-lu) provided by Dr.
D.L. Bronson (University of Minnesota, MN) were
utilized in the present study. All cell lines were
cultured in high-glucose DMEM supplemented
with 15% fetal bovine serum. In addition, ten pri-
mary GCT tumor tissues were utilized (Murty et
al., 1994).
Fluorescence In Situ Hybridization (FISH)
FISH was performed by standard methods on
normal male metaphase chromosomes and on chro-
mosomes prepared from 8 GCT cell lines. A PAC
clone, RPCI3-373G19, containing a part of the
APAF1 gene was biotin-labeled using a bionick-
labeling kit (GIBCO/BRL) and was utilized as a
probe after suppression with Cot-1 DNA. A Spec-
trum Orange-labeled chromosome 12 centromeric
probe, CEP12 (VYSIS, Downers Grove, IL), was
used to enumerate chromosome 12. Double-color
FISH was performed, and the biotin-labeled probe
was detected with fluorescein-avidin antibody.
Fluorescence signals were captured on an Applied
Imaging Cytovision Imaging System, and at least
20 metaphase cells were scored under a triple-
bypass filter with DAPI counterstain.
Isolation of RNA, Northern Blot Analysis and
Multiplex RT-PCR to Evaluate Expression
of APAF1
Total RNA was isolated utilizing a Stratagene
RNA isolation kit according to the manufacturer’s
protocol. Polyadenylated mRNA was extracted
from the frozen cell pellets of at least 2 3 107 cells
using Dyna beads (Dynal, Lake Success, NY) ac-
cording to the manufacturer’s protocol. Two micro-
grams of each mRNA sample was electrophoresed
on a 1.2% formaldehyde agarose gel and transferred
onto nylon membrane by standard procedures. The
membranes were hybridized first with APAF1
cDNA probe (734 bp of the 59UTR and 2370 bp of
the coding region) followed by a b-actin probe as
control. Five micrograms of total RNA was sub-
jected to reverse transcription using random prim-
ers and M-MuLV reverse transcriptase (Stratagene,
La Jolla, CA) in a 50-ml reaction volume for 60 min
at 37°C. Two microliters of the RT reaction prod-
uct was then subjected to multiplex PCR. The
APAF1 primers (forward 59-GCTGCCATTTCAC-
CAACAGT-39 at 2655 bp of cDNA and reverse
59-CTCTCATTTGCTGATGTCGC-39 at 2877 bp
of cDNA) crossing exons 15 and 16, that yield a 223
bp fragment, combined with b-actin primers that
give a 450 bp fragment were utilized for PCR. The
PCR products were run on a 1.5% agarose gel and
visualized by ethidium bromide staining.
Mutation Screening
SSCP analysis was performed on the entire cod-
ing region of the APAF1 gene in GCTs using 19
overlapping sets of primers derived from the cDNA
sequence (Zou et al., 1997). Five micrograms of
total RNA extracted from GCT cell lines was re-
verse-transcribed utilizing random primers in a re-
action volume of 50 ml utilizing an RT-PCR kit
(Stratagene, La Jolla, CA) according to the manu-
facturer’s protocol. The cDNAs were amplified for
35 cycles of PCR under standard conditions in the
presence of 1 mCi of [32P]dCTP (3000 Ci/ml, Am-
ersham, Piscataway, NJ) in a final reaction volume
of 25 ml. Diluted PCR products (0.1% SDS/10
mmol/L EDTA and sequencing dye) were heat-
denatured and electrophoresed on 6% nondenatur-
ing polyacrylamide gels containing 10% glycerol at
room temperature. After electrophoresis, gels were
dried and exposed to X-ray film. Autoradiographs
were examined for conformational changes. Man-
ual as well as automated sequencing was performed
on both strands of purified PCR products of sus-
pected SSCP variants.
Preparation of Cell Extracts
The S-100 cytosolic fraction was prepared from
GCT cell lines as described in Liu et al. (1996).
Briefly, the cell pellets were suspended in ice-cold
buffer A (20 mM HEPES-KOH, pH 7.5, 10 mM
KCl, 1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM
sodium EGTA, 1 mM dithiothreitol, and 0.1 mM
PMSF) by passage through an 18-gauge syringe 12
times. The supernatant from a 20 min centrifuga-
tion at 12,000 3 g was isolated and subjected to
100,000 3 g in a Sorvall G6-SR ultracentrifuge.
The remaining supernatant was collected and the
protein concentration determined using the Brad-
ford method.
Western Blot for APAF1
Anti-Apaf1 anti-serum was generated by immu-
nization of rabbits with a recombinant APAF1 fu-
sion protein (see below). One hundred micrograms
of the purified proteins, prepared from asynchro-
nous cultures of GCT cell lines extracted by stan-
dard methods, were electrophoresed on a 6% SDS-
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polyacrylamide gel and then transferred onto BA-S
83 membrane (Schleicher and Schuell, Keene,
NH). Immunoblot analysis was performed with a
horseradish peroxidase-conjugated goat anti-rabbit
(Apaf1) immunoglobulin G using Enhanced Chemi-
Luminescence (ECL) Western blotting detection
reagents (Amersham, Piscataway, NJ) (Houlds-
worth et al., 1997; Zou et al., 1997).
Production of APAF1 Fusion Protein
The primers 59- TCT TCT TCC AGT CAT
ATG ACA GTC CTG GTG-39 and 59-TTA TGT
AGA TCC TGG AGC TCG CTG CAA TTC -39
were designed to PCR-amplify a segment of the
APAF1 cDNA open reading frame, and the ampli-
fied fragment encoding amino acids 101–446 of
APAF1 was sub-cloned inframe into the NdeI/XhoI
sites of the bacterial expression vector pET-15b
(Novagen, Madison). The sub-cloned PCR-de-
rived clones were sequenced to confirm that it
contained normal cDNA sequence before utilizing
in expression studies. The expression plasmid was
transformed into bacteria BL21 (DE3). In a typical
APAF1 preparation, a 5-ml overnight culture of
bacteria containing APAF1 expression vector was
added into a 500 ml LB broth, and cultured for 3 hr
by shaking at 220 rpm at 37°C. Isopropyl-1-thio-B-
D-galactopyranoside (IPTG) was added to the cul-
ture at a final concentration of 1 mM with contin-
ued shaking for another 2 h. The bacteria were
pelleted by centrifugation, and the bacterial pellet
was resuspended in 10 ml of buffer B (6 M GuHCl,
0.1 M sodium phosphate, 0.01 M Tris-HCl, pH
8.0). After centrifugation at 10,000 3 g for 15 min,
the supernatant was loaded onto a nickel affinity
column (6 ml). The column was washed with 300
ml of buffer B followed by 300 ml of buffer C (8 M
urea, 0.1 M sodium phosphate, 0.01 M Tris-HCl,
pH 8.0). The column was eluted with buffer C
containing 250 mM imidazole.
Assay for Caspase-3 Activation
Caspase-3 was translated and purified as de-
scribed (Liu et al., 1996). A 2 ml aliquot of the in
vitro translated caspase-3 was incubated at 30°C for
the indicated time period with a protein fraction in
the presence of 1 mM dATP and 1 mM of addi-
tional MgCl2 brought to a final volume of 30 ml of
buffer A (20 mM HEPES-KOH, pH 7.5, 10 mM
KCl, 1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM
sodium EGTA, 1 mM dithiothreitol, and 0.1 mM
PMSF). At the end of the incubation, 10 ml of 43
SDS sample buffer was added to each reaction.
After boiling for 3 min, each sample was subjected
to 15% SDS-polyacrylamide gel electrophoresis.
The gel was transferred to a nitrocellulose filter
that was subsequently exposed to a PhosphorIm-
ager plate and visualized in a Fuji BAS-1000 Phos-
phorImager.
RESULTS
Mapping of APAF1 Gene Between Polymorphic
Markers D12S296 and D12S346
A database search of the sequence obtained from
the PAC clone 373G19-T7 mapped to 12q22 iden-
tified 169 bp of APAF1 cDNA sequence, that was
subsequently identified as exon 9. Additional
screening of PAC and BAC libraries utilizing end
sequences generated from P373G19 resulted in
identification of 12 additional clones (11 BACs and
one PAC). Several existing YACs (Murty et al.,
1996) and the clones obtained here were screened
for STS content utilizing P373G19 end markers,
and 13 previously mapped markers (8 STSs, 3
ESTs, and 2 genes) (Kucherlapati et al., 1997;
Murty et al., 1999). An additional primer set gen-
erated from the 59 end of the APAF1 coding region
was also utilized in the analysis. This analysis
mapped the APAF1 gene between the polymorphic
markers D12S296 and D12S346 at a 106-cM ge-
netic distance on the chromosome 12 genetic map
(Dib et al., 1996) (Fig. 1A). More precisely, APAF1
is mapped between the loci TMPO/PHC/D29485
proximally and D12S1218E/D12S1098 distally.
This analysis also identified 4 BACs (B396N22,
B7L14, B481K9, B313A8) that contained all or
most of the 59 end of the APAF1 gene, and 9 other
clones (B12B10, B170A13, B170I13, B453P16,
B548D10, P490A19, P373G19, B14P19, B14P21)
that contained all or most of the 39 end of the gene.
The STS-content analysis also determined the
transcriptional orientation of the gene from the
centromeric to telomeric ends (Fig. 1A).
Intron-Exon Structure of APAF1
The overlapping clones P373G19, B396N22, and
B7L14 identified by physical mapping containing
the entire APAF1 cDNA sequence were utilized to
identify intron-exon boundaries. BLAST compari-
sons of the generated sequences identified all the
intronic boundaries. The APAF1 gene was found
to consist of 27 exons and 26 introns (Table 1,
Fig. 1B, GenBank accession Nos. AF098868-
AF098914). The coding region of APAF1 spanned
26 exons, with the translation initiation site (ATG)
located at nucleotide position 578 in exon 2, pre-
ceded by 59-UTR within exon 2 and exon 1, and
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with the 39 end of the coding region ending at
nucleotide position 4159 in exon 27. Exon 27 (3007
bp) encodes the last 49 aa, followed by a large
39-UTR of 2863 bp (Fig. 1B). Exon 18 represents
an alternatively spliced exon, that results in an
additional WD repeat in the protein (Zou et al.,
1999). We also determined the size of 6 small
introns by complete sequencing (Table 1). The
APAF1 gene spans about 55 kb of the genomic
region, as estimated from the size of fragments
hybridizing to full-length cDNA (data not shown).
Analysis of Mutations and mRNA Expression
We utilized the P373G19 clone to confirm the
APAF1 map position by FISH on normal human
metaphase chromosomes. All 30 metaphase cells
Figure 1. Mapping of APAF1 gene. (A) Physical mapping of APAF1
gene between polymorphic markers D12S296 and D12S346. The map
comprised of 5 YACs (denoted by ‘y’), 11 BACs (denoted by ‘B’), and
2 PACs (denoted by ‘P’). Solid bar on the top represents chromosomal
region in centromeric (cen) to telomeric (tel) orientation. The markers
placed on the map are shown above the solid bar by vertical lines
(distances on the map are not to scale). Thin brackets facing upward
indicate that the relative order of the markers could not be determined.
Numbers below the solid bar indicate the genetic map positions on
chromosome 12. Solid circle, polymorphic marker; solid square, non-
polymorphic marker; downward triangle, EST; upward triangle, gene;
thin empty square, marker not tested; thick empty square, clone-end
marker generated by sequencing of the end. A bracket within a YAC
indicates an internal deletion. TMPO, thymopoietin; PHC, phosphate
carrier mitochondrial; APAF1, apoptotic protease activating factor-1.
(B) Schematic representation of genomic organization of APAF1 gene
showing exons and the corresponding protein domains. Black boxes
represent coding exons and hatched boxes noncoding exons (drawn to
scale) (top), connected by dotted lines as intervening sequences (not
drawn to scale). Protein structure at the bottom shows different
domains, amino-acid (aa) positions, and their corresponding coding
exons by broken vertical lines. A and B in the CED-4 domain indicate
consensus sequences for nucleotide binding. Exon 18 represents an
alternatively spiced exon resulting in an additional WD 40 repeat (not
represented in the figure).






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































analyzed showed signals only at 12q22 (data not
shown). FISH analysis identified APAF1 gene de-
letions in 2 of 8 (25%) GCT cell lines (268A, 218A),
that exhibited fewer P373G19 signals compared to
centromeric signals (Fig. 2A). To ascertain whether
APAF1 is a candidate TSG, RT-PCR using over-
lapping sets of primers spanning the entire coding
region was performed, followed by SSCP analysis
on 17 GCT cell lines and 10 primary tumors. No
mutations were found.
Northern analysis of poly A1 RNA was per-
formed on 8 GCT cell lines hybridized with a
cDNA probe to assess the levels of APAF1 mRNA.
No APAF1 mRNA was detected in any cell line,
whereas the control b-actin showed abundant ex-
pression, suggesting undetectable levels or lack of
expression of APAF1 mRNA in GCT cell lines
(data not shown). To assess the APAF1 expression
further, 35 cycles of multiplex RT-PCR were per-
formed on cDNA using primers spanning 2 differ-
ent exons of the gene. All 12 cell lines and 6
primary tumors analyzed showed detectable levels
of APAF1 message (Fig. 2B).
APAF1 Protein Expression and Analysis of Its
Activity by Caspase-3 Cleavage
To assess the levels of APAF1 protein, we per-
formed Western blot analysis on 17 GCT cell lines
using polyclonal antibody directed against the
CED-4 domain of APAF1. All cell lines analyzed
showed appropriate-size immunoreactive bands
against APAF1 antibody, with a considerable varia-
tion in protein levels. The Tera-2 and Tera-1 cell
lines showed an abnormal protein of smaller molec-
ular weight (’120 kD) in addition to a normal-size
protein (Fig. 2C). That this variant represents an
alternatively spliced form of APAF1 has not been
ruled out. Variant forms of alternatively spliced
APAF1 due to additional WD40 repeats have been
reported in human (Hu et al., 1999; Zou et al., 1999)
Figure 2. Genetic analysis of APAF1. (A) Identification of deletions at
the 12q22 region containing APAF1 gene using a PAC clone 373G19 as
probe by double color FISH. Partial metaphases with DAPI counter
stain showing centromeric (orange) and P379G19 (green) signals. Cell
lines 218A (left) and 268A (right) with deleted chromosome 12 are
indicated by arrows. (B) RT-PCR analysis of APAF1 gene expression in
GCTs. b-actin was used as an internal control. (C) Western blot
analysis of APAF1. Aliquots of 100 mg lysates were subjected to 6%
SDS-PAGE and electroblotted, and then the filters were probed with a
polyclonal anti-Apaf-1 antibody (see Methods). APAF1 reactive bands
were identified by comparing with the position of purified Apaf-1. The
position of the APAF1 is indicated on the gel. Asterisks indicate aber-
rant-size bands.
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as well as in mouse (Cecconi et al., 1998) cells.
WD-40 repeats in APAF1 play a role in recruiting
procaspase-3 to the APAF1-caspase-9 complex. Mu-
tants carrying deletion in the WD-40 region fail to
activate procaspase-3 and are deficient in apoptosis
(Hu et al., 1999).
APAF1 functions to mediate the activation of
caspase-3 in response to exposure to cytochrome c
and dATP (Li et al., 1997; Zou et al., 1997). To
examine whether 12q22 deletions in GCT affect
APAF1 function, we assayed S-100 cytosolic ex-
tracts for dATP-induced cleavage of in vitro trans-
lated radio-labeled caspase-3 as a marker for
APAF1 activity. Of seven GCT cell lines tested,
three (Tera-2, 218A, and 268A) showed lack or
decrease in dATP-mediated caspase-3 cleavage
(Fig. 3A,B). In Tera-2, the cell line that showed the
aberrant protein, the cell extract exhibited unde-
tectable or no activity at low concentrations of
S-100 (10 and 20 mg), and a detectable level of
activity was seen only when large amounts of pro-
tein (30 mg) were used. In the other cell lines
(169A, 2102E-R, and 175A), a high level of activity
was detected with as little as 10 mg protein (Fig.
3A). The cell lines 268A and 218A showed no
dATP-mediated APAF1 activity even after addi-
tion of large amounts of protein to the reaction
mixture (80 mg for 268A and 120 mg for 218A) (Fig.
3B). This lack of APAF1 activity correlates with
genetic deletions seen by FISH in the cell lines
268A and 218A.
To determine whether this lack or decreased
caspase-3 activity was due to disruption of APAF1
protein expression, we performed Western blot
analysis that confirmed the presence of appropri-
ately sized immunoreactive bands in all of the cell
extracts examined (Fig. 2B and data not shown).
Because the activation of caspase-3 is dependent
Figure 3. Analysis of dATP-dependent caspase-3 activation in GCT
cell lines. (A) Left panel: aliquots (2 ml) of in vitro-translated, 35S-
labeled, and affinity-purified caspase-3 were incubated at 30°C for 1.5 hr
with 10 mg (lanes 1, 2, 7, 8), 20 mg (3, 4, 9, 10) or 30 mg (5, 6, 11, 12)
of S-100 from Tera-2 or 169A cell lines. Right panel: aliquots (2 ml) of
35S caspase-3 were incubated at 30°C with 30 mg of S-100 from Tera-2
or 169A cell lines for 15 min (lanes 1, 2, 7, 8), 30 min (3, 4, 9, 10) or 45
min (5, 6, 11, 12) in the presence (lanes 2, 4, 6, 8, 10, 12) or absence
(lanes 1, 3, 5, 7, 9, 11) of 1 mM dATP and 1 mM MgCl2 in a final volume
of 32 ml. (B) Aliquots (2 ml) of in vitro-translated, 35S-labeled, and
affinity-purified caspase-3 were incubated at 30°C for 2.5 hr with 80 mg
aliquots of GCT S-100 from cell lines 218A (lanes 1, 2), 268A (lanes 3,
4), 2102E-R (lanes 5, 6) or 175A (lanes 7, 8) in the presence (lanes 2, 4,
6, 8) or absence (lanes 1, 3, 5, 7) of 1 mM dATP and 1 mM MgCl2 in a
final volume of 32 ml. (C) Aliquots (2 ml) of in vitro-translated, 35S-
labeled, and affinity-purified caspase-3 were incubated at 30°C for 4 hr
with 30 mg aliquots of S-100 from cell lines 218A (lanes 1–8) or
2102E-R (lanes 9, 10) supplemented with 200 ng of cytochrome c
(Sigma) in the presence (lanes 2, 4, 6, 8, 10) or absence (lanes 1, 3, 5,
7, 9) of 1 mM dATP and 1 mM MgCl2 in a final volume of 30 ml. Samples
were additionally supplemented with either 300 ng of recombinant
APAF1 (lanes 3, 4, 7, 8) or 65 ng of recombinant caspase-9 (lanes 5–8).
In all experiments, after incubation, samples were subjected to 15%
SDS-PAGE and transferred to nitrocellulose filters. The filters were
exposed overnight to a phosphorimaging plate at room temperature.
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on the presence of APAF1, cytochrome c, and
caspase-9, these proteins were added back to S-100
to determine which components were deficient in
the GCT cell lines that showed a lack of or de-
crease in activity. Figure 3C shows the results after
supplementation of these protein components in
cell extract from the 218A cell line. Similar results
were obtained for 268A extracts (data not shown).
Cytochrome c is abundantly present in the S-100
cytosolic fraction (Kim et al., 1997) and addition of
cytochrome c had no effect on activation of dATP-
dependent activity (Fig. 3C, lanes 1 and 2). Addi-
tion of recombinantly expressed APAF1 showed
only a marginal increase in dATP activation of
caspase-3 cleavage (Fig. 3C, lanes 3 and 4). Intro-
duction of recombinant caspase 9 markedly in-
creased the activity in the cell line (Fig. 3C, lanes
5 and 6). The activity of the recombinant protein is
demonstrated by co-addition to the cell extract
(Fig. 3C, lanes 7 and 8). These data indicate that
the deficiency in caspase-3 activation in these ex-
tracts is not due to the absence of active APAF1
protein.
DISCUSSION
The 12q22 band has been suggested to harbor a
potential TSG in male GCTs (Murty et al., 1990;
Samaniego et al., 1990; Murty et al., 1992, 1996,
1999; Rodgriguez et al., 1992 ). The same region
has also been shown to be frequently deleted in
pancreatic carcinomas (Hahn et al., 1995; Kimura et
al., 1996, 1998). These studies strongly implicated
the presence of a TSG at 12q22. In an attempt at
positional cloning of the candidate TSG, we
mapped the APAF1 gene immediately distal to the
common region of deletion in GCTs. In view of the
critical role played by the APAF1 gene in the apo-
ptotic pathway, we considered the gene as a strong
candidate TSG for 12q22 deletions and examined
its role in GCT. The initial FISH analysis identi-
fied APAF1 deletions in 25% of GCT cell lines.
These data provided evidence that the APAF1
gene is within a deleted segment of 12q22 in a
certain proportion of GCTs, thus leading to further
analyses of the gene in these tumors. It has previ-
ously been shown that one of the cell lines (218A)
exhibited LOH at 12q22 (Murty et al., 1996). Sim-
ilarly, 57% (four of seven) pancreatic carcinoma cell
lines analyzed also showed deletions of the APAF1
gene (data not shown).
To find whether the APAF1 gene functions as a
TSG, we studied genetic and functional alterations
of the gene in GCTs. Lack of mutations in APAF1
suggested that the gene is not inactivated by mech-
anisms involving loss of function. We also have not
found any mutations in 8 pancreatic carcinoma cell
lines analyzed (data not shown). Consistent with
this, we did not find any gross genomic alterations
in the APAF1 gene in 45 GCT DNAs studied by
Southern blot analysis (data not shown). To exam-
ine the APAF1 expression, we first examined
mRNA by Northern analysis and could not find any
detectable levels of expression in GCT cell lines.
We then determined whether APAF1 was ex-
pressed by RT-PCR and protein by Western blot
analysis. Both mRNA and proteins were detected
in all GCTs analyzed, including the Tera-2 cell
line that exhibited an aberrant-sized protein.
To determine whether the genetic deletions and
the variations in mRNA and protein affect the
functional activity of APAF1, we assessed
caspase-3 activation in GCT cell lines. We mea-
sured the activity of dATP-dependent, APAF1-
mediated caspase-3 cleavage in the Tera-2 cell
line, which showed an aberrant-sized protein, at
various concentrations of S-100 with different in-
cubation periods. Caspase-3 was not activated at
low concentrations of protein and at shorter incu-
bation periods with these cells, in contrast to
marked cleavage of caspase-3 in other cell lines
(e.g., 169A). Detectable caspase-3 cleavage was
seen in Tera-2 only after addition of a high con-
centration of protein and prolonged incubation
times. In two other GCT cell lines, 218A and 268A,
that exhibited APAF1 gene deletions, the dATP-
dependent activation of caspase cleavage was
found to be defective, without any detectable
forms of active caspase-3 even at higher concentra-
tions of protein with prolonged incubation periods
(Fig. 3B). Utilizing similar conditions, the cell lines
2102E-R and 175A, that did not exhibit APAF1
genomic deletions, showed markedly higher levels
of caspase-3 cleavage. Hence, these data suggest
that the cell lines 218A and 268A are defective in
the dATP-dependent apoptotic pathway.
To determine whether this decrease or lack of
active caspase-3 is due to relative levels of APAF1
or other components in the pathway, we added
recombinant APAF1 and caspase-9 in these exper-
iments. Addition of recombinant APAF1 did not
restore caspase activation in cell line 218A (Fig.
3C). Identical results were obtained with the cell
line 268A (results not shown). Recombinant
APAF1 has been shown to promote the activation
of caspase-3 in the presence of recombinant
caspase-9 and pure cytochrome c or in by addition
to Apaf-1 2/2 fibroblast extracts (Zou et al., 1999).
These data, thus, suggest that the defect is not due
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to a disruption of the APAF1 gene itself. This
latent activity was best demonstrated by addition
of purified recombinant caspase-9, that exhibited
detectable active caspase-3 in the cell line 218A
(Fig. 3C, lanes 5 and 6). Supplementation of
caspase-9 with or without addition of APAF1 re-
stored the caspase-3 cleavage, although a marked
increase occurred when both components were
added. Because the caspase-9 protein was detect-
able in all cell lines by Western analysis (data not
shown), these data suggest that the defect in
dATP-mediated caspase activation may be in an
endogenous regulatory pathway or due to a domi-
nant-negative form of APAF1 that might compete
for caspase-9 recruitment. No evidence for domi-
nant-negative mutations was found, however, by
examination of the APAF1 mRNA transcript in
these cells by SSCP analysis. Whereas the defect is
not directly due to a disruption of APAF1 expres-
sion, the link between genomic deletions contain-
ing APAF1 and the dATP activation of caspase
cleavage is intriguing. These deletions may also
point to the regulated inactivation of caspase-9 or
perhaps other components of the APAF1-mediated
pathway for caspase activation in response to dis-
ruption of another gene in the 12q22 deleted re-
gion tightly linked to the APAF1 gene. It is now
known that at least one other gene, RAIDD (Rip-
associated ICH1/CED3-homologous protein with
death domain), that controls apoptosis is mapped to
the 12q22 region. The growth-factor-dependent
regulation of BAD phosphorylation and the bind-
ing to Bcl-X demonstrate that such connections
exist between cell cycle controls and apoptosis for
other arms of the apoptotic control machinery
(Datta et al., 1997; del Peso et al., 1997). Taken
together, these data do not support a role for
APAF1 as a candidate TSG targeting 12q22 dele-
tions in GCT. It remains to be seen, however,
whether other mechanisms involving downstream
genes in the pathway play a role in tumorigenesis
in these tumors. The genomic structure of the
APAF1 gene generated in the present study would
be of relevance in facilitating further studies in this
direction in normal and disease states.
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